You are here:

olodaterol respimat (Striverdi Respimat)

Advice

following a re-submission

olodaterol (Striverdi® Respimat®) is accepted for use within NHS Scotland.

Indication under review: maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease.

In two 48-week studies there was no significant difference between olodaterol 5 microgram and another long acting beta2 agonist for the primary endpoints of trough forced expiratory volume in 1 second (FEV1) and FEV1 area under curve (0 to 3 hours) at week 24.

Drug Details

Drug Name: olodaterol respimat (Striverdi Respimat)
SMC Drug ID: 974/14
Manufacturer: Boehringer Ingelheim Ltd
Indication: Maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease.
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 12 January 2015

Archived Advice

Full submission 11 August 2014

Back